<p>ImmuCell Corporation（納斯達克代碼：ICCC - 獲取免費報告）在 12 月份的空頭頭寸大幅增長。截至 12 月 15 日，空頭頭寸總計為 15,418 股，比 11 月 30 日的 6,239 股增長了 147.1%。目前，該公司的 0.2% 股份被做空。根據 18,731 股的平均交易量，當前的覆蓋天數比率為 0.8 天。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Weiss Ratings 在週一的報告中重申了對 ImmuCell 股票的 “賣出（d+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat.com 的數據，ImmuCell 的平均評級為 “賣出”。</p>
<p><strong>查看我們對 ICCC 的最新股票分析</strong></p>
<h2>ImmuCell 價格表現</h2>
<p>週五午盤交易中，ICCC 的股票上漲了 0.32 美元，達到了 6.12 美元。該股票的交易量為 336,206 股，而其平均交易量為 20,020 股。該公司的 50 日移動平均為 5.69 美元，200 日移動平均為 6.15 美元。公司的債務與股本比率為 0.27，速動比率為 1.76，流動比率為 4.21。該公司的市值為 5539 萬美元，市盈率為 23.54，貝塔值為 0.20。ImmuCell 的 12 個月低點為 4.28 美元，12 個月高點為 7.60 美元。</p>
<p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）最近於 11 月 13 日發佈了其財報。這家生物技術公司報告了該季度每股收益為（0.02）美元。ImmuCell 的淨利潤率為 8.37%，股本回報率為 8.00%。該公司該季度的收入為 551 萬美元。</p>
<h2>ImmuCell 的機構交易</h2>
<p>一家機構投資者最近增加了對 ImmuCell 股票的持倉。根據該公司最近向證券交易委員會提交的 13F 文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股增加了 4.2%。該機構投資者在此期間購買了 2,907 股後，持有 71,852 股生物技術公司的股票。根據其最近的 SEC 文件，Geode Capital Management LLC 持有的 ImmuCell 股份價值 50 萬美元，佔該公司股份的 0.79%。機構投資者持有該公司 13.47% 的股份。</p>
<h2>關於 ImmuCell</h2>
<p>（獲取免費報告）</p>
<p>ImmuCell Corporation（納斯達克代碼：ICCC）是一家生物技術公司，開發、製造和銷售旨在增強奶牛和肉牛健康的免疫產品和診斷試劑。公司總部位於緬因州波特蘭，專注於通過其被動免疫解決方案和獸醫診斷產品支持羣體健康管理。</p>
<p>該公司的旗艦產品 CalfGuard 天然初乳補充劑旨在促進新生小牛抗體的被動轉移，並減少新生疾病的發生率。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 ImmuCell 更好</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>華盛頓準備開戰</li>
<li>你的 “出生權索賠” 剛剛被激活</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 ImmuCell 嗎？</h2>
<p>在你考慮 ImmuCell 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
<p>儘管 ImmuCell 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ICCC

<p>ImmuCell Corporation（納斯達克代碼：ICCC）在 12 月份的空頭頭寸增加了 147.1%，總計達到 15,418 股。覆蓋天數比率為 0.8 天，賣空股份佔比為 0.2%。Weiss Ratings 重申了 “賣出” 評級。該股票上漲了 0.32 美元，報 6.12 美元，市值為 5539 萬美元。機構投資者持有該股票的 13.47%。ImmuCell 專注於乳牛和肉牛的動物健康產品</p>

<p>ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 15,418 shares, a growth of 147.1% from the November 30th total of 6,239 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 18,731 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.2% of the shares of the company are short sold.</p>
<div class="lb-trans"><p>ImmuCell Corporation（納斯達克代碼：ICCC - 獲取免費報告）在 12 月份的空頭頭寸大幅增長。截至 12 月 15 日，空頭頭寸總計為 15,418 股，比 11 月 30 日的 6,239 股增長了 147.1%。目前，該公司的 0.2% 股份被做空。根據 18,731 股的平均交易量，當前的覆蓋天數比率為 0.8 天。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of ImmuCell in a report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ImmuCell has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在週一的報告中重申了對 ImmuCell 股票的 “賣出（d+）” 評級。一位股票研究分析師對該股票給予了賣出評級，根據 MarketBeat.com 的數據，ImmuCell 的平均評級為 “賣出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on ICCC</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ICCC 的最新股票分析</strong></p>
</div><h2>ImmuCell Price Performance</h2>
<div class="lb-trans"><h2>ImmuCell 價格表現</h2>
</div><p>Shares of ICCC traded up $0.32 during mid-day trading on Friday, reaching $6.12. The stock had a trading volume of 336,206 shares, compared to its average volume of 20,020. The business has a fifty day moving average of $5.69 and a 200 day moving average of $6.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. The firm has a market cap of $55.39 million, a price-to-earnings ratio of 23.54 and a beta of 0.20. ImmuCell has a 12 month low of $4.28 and a 12 month high of $7.60.</p>
<div class="lb-trans"><p>週五午盤交易中，ICCC 的股票上漲了 0.32 美元，達到了 6.12 美元。該股票的交易量為 336,206 股，而其平均交易量為 20,020 股。該公司的 50 日移動平均為 5.69 美元，200 日移動平均為 6.15 美元。公司的債務與股本比率為 0.27，速動比率為 1.76，流動比率為 4.21。該公司的市值為 5539 萬美元，市盈率為 23.54，貝塔值為 0.20。ImmuCell 的 12 個月低點為 4.28 美元，12 個月高點為 7.60 美元。</p>
</div><p>ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The firm had revenue of $5.51 million for the quarter.</p>
<div class="lb-trans"><p>ImmuCell（納斯達克代碼：ICCC - 獲取免費報告）最近於 11 月 13 日發佈了其財報。這家生物技術公司報告了該季度每股收益為（0.02）美元。ImmuCell 的淨利潤率為 8.37%，股本回報率為 8.00%。該公司該季度的收入為 551 萬美元。</p>
</div><h2>Institutional Trading of ImmuCell</h2>
<div class="lb-trans"><h2>ImmuCell 的機構交易</h2>
</div><p>An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC increased its holdings in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company's stock after purchasing an additional 2,907 shares during the period. Geode Capital Management LLC owned 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Institutional investors own 13.47% of the company's stock.</p>
<div class="lb-trans"><p>一家機構投資者最近增加了對 ImmuCell 股票的持倉。根據該公司最近向證券交易委員會提交的 13F 文件，Geode Capital Management LLC 在第二季度將其在 ImmuCell Corporation（納斯達克代碼：ICCC - 免費報告）的持股增加了 4.2%。該機構投資者在此期間購買了 2,907 股後，持有 71,852 股生物技術公司的股票。根據其最近的 SEC 文件，Geode Capital Management LLC 持有的 ImmuCell 股份價值 50 萬美元，佔該公司股份的 0.79%。機構投資者持有該公司 13.47% 的股份。</p>
</div><h2>About ImmuCell</h2>
<div class="lb-trans"><h2>關於 ImmuCell</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.</p>
<div class="lb-trans"><p>ImmuCell Corporation（納斯達克代碼：ICCC）是一家生物技術公司，開發、製造和銷售旨在增強奶牛和肉牛健康的免疫產品和診斷試劑。公司總部位於緬因州波特蘭，專注於通過其被動免疫解決方案和獸醫診斷產品支持羣體健康管理。</p>
</div><p>The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.</p>
<div class="lb-trans"><p>該公司的旗艦產品 CalfGuard 天然初乳補充劑旨在促進新生小牛抗體的被動轉移，並減少新生疾病的發生率。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than ImmuCell</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>Washington prepares for war</li>
<li>Your “birthright claim” just got activated</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 ImmuCell 更好</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>華盛頓準備開戰</li>
<li>你的 “出生權索賠” 剛剛被激活</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ImmuCell Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 ImmuCell 嗎？</h2>
</div><p>Before you consider ImmuCell, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 ImmuCell 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ImmuCell 並不在名單上。</p>
</div><p>While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 ImmuCell 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ImmuCell 公司（NASDAQ: ICCC）在 12 月份的空頭頭寸增長了 147.1%